- Achieved significant enrollment milestone in pivotal Phase 3 trial of IO102-IO103 cancer vaccine in advanced melanoma; full enrollment anticipated by the end of 2023
- Initiated enrollment in three investigator-initiated trials which the company is supporting to evaluate IO102-IO103 in combination regimens across a variety of cancer types
- Continued enrollment in Phase 2 basket trial of IO102-IO103, in patients with lung cancer, and head and neck cancer
- Strengthened executive team with hires to key commercial and medical leadership positions
- Completed a $75 million private placement with participation from both new and existing healthcare-dedicated investors
- Ended the second quarter with approximately $110.1 million in cash and cash equivalents, which, together with the proceeds from the private placement financing, is expected to support operations into the fourth quarter of 2025
Read more…
